Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1960 1
1961 1
1967 1
1971 1
1972 1
1975 3
1976 9
1977 5
1978 9
1979 3
1980 11
1982 4
1983 6
1984 12
1985 8
1986 16
1987 16
1988 10
1989 10
1990 16
1991 12
1992 10
1993 8
1994 9
1995 9
1996 15
1997 16
1998 18
1999 15
2000 12
2001 27
2002 20
2003 27
2004 17
2005 22
2006 27
2007 20
2008 15
2009 18
2010 32
2011 16
2012 21
2013 23
2014 20
2015 23
2016 25
2017 23
2018 21
2019 26
2020 33
2021 23
2022 30
2023 28
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

750 results

Results by year

Filters applied: . Clear all
Page 1
Update omicronn the diagnosis and management of systemic lupus erythematosus.
Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Fanouriakis A, et al. Ann Rheum Dis. 2021 Jan;80(1):14-25. doi: 10.1136/annrheumdis-2020-218272. Epub 2020 Oct 13. Ann Rheum Dis. 2021. PMID: 33051219 Free article. Review.
Clinical heterogeneity, unpredictable course and flares are characteristics of systemic lupus erythematosus (SLE). Although SLE is-by and large-a systemic disease, occasionally it can be organ-dominant, posing diagnostic challenges. ...For organ-threatening or life-threate …
Clinical heterogeneity, unpredictable course and flares are characteristics of systemic lupus erythematosus (SLE). Although SLE is-by and la …
A Pituitary Society update to acromegaly management guidelines.
Fleseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L, Molitch ME, Samson SL, Strasburger CJ, van der Lely AJ, Melmed S. Fleseriu M, et al. Pituitary. 2021 Feb;24(1):1-13. doi: 10.1007/s11102-020-01091-7. Epub 2020 Oct 20. Pituitary. 2021. PMID: 33079318 Free PMC article. Review.
Given significant novel recent advances in understanding acromegaly natural history and individualized therapies, the Pituitary Society invited acromegaly experts to critically review the current literature in the context of Endocrine Society guidelines and Acromegaly Cons …
Given significant novel recent advances in understanding acromegaly natural history and individualized therapies, the Pituitary Socie …
ACG Clinical Guideline: Diagnosis and Management of Pancreatic Cysts.
Elta GH, Enestvedt BK, Sauer BG, Lennon AM. Elta GH, et al. Am J Gastroenterol. 2018 Apr;113(4):464-479. doi: 10.1038/ajg.2018.14. Epub 2018 Feb 27. Am J Gastroenterol. 2018. PMID: 29485131 Review.
However, even the types of cysts with malignant potential rarely progress to cancer. At the present time, the only viable treatment for pancreatic cysts is surgical excision, which is associated with a high morbidity and occasional mortality. ...This guidelin …
However, even the types of cysts with malignant potential rarely progress to cancer. At the present time, the only viable treatment f …
Clinical Practice Guideline for the Management of Infantile Hemangiomas.
Krowchuk DP, Frieden IJ, Mancini AJ, Darrow DH, Blei F, Greene AK, Annam A, Baker CN, Frommelt PC, Hodak A, Pate BM, Pelletier JL, Sandrock D, Weinberg ST, Whelan MA; SUBCOMMITTEE ON THE MANAGEMENT OF INFANTILE HEMANGIOMAS. Krowchuk DP, et al. Pediatrics. 2019 Jan;143(1):e20183475. doi: 10.1542/peds.2018-3475. Pediatrics. 2019. PMID: 30584062 Review.
Infantile hemangiomas (IHs) occur in as many as 5% of infants, making them the most common benign tumor of infancy. Most IHs are small, innocuous, self-resolving, and require no treatment. ...Treatment typically is continued for at least 6 months and often is maintained un …
Infantile hemangiomas (IHs) occur in as many as 5% of infants, making them the most common benign tumor of infancy. Most IHs are smal …
Multidisciplinary management of acromegaly: A consensus.
Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B, Boguszewski C, Bolanowski M, Bollerslev J, Bonert V, Bronstein MD, Buchfelder M, Casanueva F, Chanson P, Clemmons D, Fleseriu M, Formenti AM, Freda P, Gadelha M, Geer E, Gurnell M, Heaney AP, Ho KKY, Ioachimescu AG, Lamberts S, Laws E, Losa M, Maffei P, Mamelak A, Mercado M, Molitch M, Mortini P, Pereira AM, Petersenn S, Post K, Puig-Domingo M, Salvatori R, Samson SL, Shimon I, Strasburger C, Swearingen B, Trainer P, Vance ML, Wass J, Wierman ME, Yuen KCJ, Zatelli MC, Melmed S. Giustina A, et al. Rev Endocr Metab Disord. 2020 Dec;21(4):667-678. doi: 10.1007/s11154-020-09588-z. Epub 2020 Sep 10. Rev Endocr Metab Disord. 2020. PMID: 32914330 Free PMC article. Review.
Focused discussions reviewed techniques, results, and side effects of surgery, radiotherapy, and medical therapy, and how advances in technology and novel techniques have changed the way these modalities are used alone or in combination. Effects of treatment on patient out …
Focused discussions reviewed techniques, results, and side effects of surgery, radiotherapy, and medical therapy, and how advances in …
The immune contexture in cancer prognosis and treatment.
Fridman WH, Zitvogel L, Sautès-Fridman C, Kroemer G. Fridman WH, et al. Nat Rev Clin Oncol. 2017 Dec;14(12):717-734. doi: 10.1038/nrclinonc.2017.101. Epub 2017 Jul 25. Nat Rev Clin Oncol. 2017. PMID: 28741618 Review.
Indeed, the local immune infiltrate undergoes dynamic changes that accompany a shift from a pre-existing immune response to a therapy-induced immune response. As a result, the immune contexture, which is determined by the density, composition, functional state and organiza …
Indeed, the local immune infiltrate undergoes dynamic changes that accompany a shift from a pre-existing immune response to a therapy …
Acquired disorders with hypopigmentation: A clinical approach to diagnosis and treatment.
Saleem MD, Oussedik E, Picardo M, Schoch JJ. Saleem MD, et al. J Am Acad Dermatol. 2019 May;80(5):1233-1250.e10. doi: 10.1016/j.jaad.2018.07.070. Epub 2018 Sep 17. J Am Acad Dermatol. 2019. PMID: 30236514 Review.
Although hypopigmentation is often asymptomatic and benign, occasional serious and disabling conditions present with cutaneous hypopigmentation. ...
Although hypopigmentation is often asymptomatic and benign, occasional serious and disabling conditions present with cutaneous hypopi …
European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer.
Meattini I, Becherini C, Boersma L, Kaidar-Person O, Marta GN, Montero A, Offersen BV, Aznar MC, Belka C, Brunt AM, Dicuonzo S, Franco P, Krause M, MacKenzie M, Marinko T, Marrazzo L, Ratosa I, Scholten A, Senkus E, Stobart H, Poortmans P, Coles CE. Meattini I, et al. Lancet Oncol. 2022 Jan;23(1):e21-e31. doi: 10.1016/S1470-2045(21)00539-8. Lancet Oncol. 2022. PMID: 34973228 Review.
Fewer treatment visits are welcomed by patients and their families, and reduced fractions produce substantial savings for health-care systems. Implementation of hypofractionation, however, has moved at a slow pace. ...Ultrafractionation (five fractions) can also be offered …
Fewer treatment visits are welcomed by patients and their families, and reduced fractions produce substantial savings for health-care …
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS; Society for Immunotherapy of Cancer Toxicity Management Working Group. Puzanov I, et al. J Immunother Cancer. 2017 Nov 21;5(1):95. doi: 10.1186/s40425-017-0300-z. J Immunother Cancer. 2017. PMID: 29162153 Free PMC article.
The majority of irAEs are mild to moderate in severity; however, serious and occasionally life-threatening irAEs are reported in the literature, and treatment-related deaths occur in up to 2% of patients, varying by ICI. ...Here we present their consensus recommendations o …
The majority of irAEs are mild to moderate in severity; however, serious and occasionally life-threatening irAEs are reported in the …
Management of immune-related adverse events and kinetics of response with ipilimumab.
Weber JS, Kähler KC, Hauschild A. Weber JS, et al. J Clin Oncol. 2012 Jul 20;30(21):2691-7. doi: 10.1200/JCO.2012.41.6750. Epub 2012 May 21. J Clin Oncol. 2012. PMID: 22614989 Review.
We review the literature on managing the adverse effects and kinetics of tumor regression with ipilimumab and provide guidelines on their management. ...Unique kinetics of response have been observed with CTLA-4 blockade with at least four patterns: (1) response in baselin …
We review the literature on managing the adverse effects and kinetics of tumor regression with ipilimumab and provide guidelines on t …
750 results